

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **APPOINTMENT OF DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES**

### **APPOINTMENT OF DIRECTORS**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that with effect from 8 April 2025:

- (i) Mr. Young Yuk Chuen David (“**Mr. Young**”) has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the “**ESG Committee**”); and
- (ii) Mr. Duan Weiwu (“**Mr. Duan**”) has been appointed as an independent non-executive Director, and a member of the audit committee (the “**Audit Committee**”) and the nomination committee (the “**Nomination Committee**”).

The biographical details of Mr. Young and Mr. Duan are set out as follows:

**Mr. Young Yuk Chuen David (楊玉川)**, aged 27, has obtained his bachelor’s degree of science, in operations management and management and leadership from Boston College in May 2020 and his master’s degree in management from Institut Européen d’Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group’s international investment projects and development for overseas business.

Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023.

Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guido Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).

The Company entered into a service agreement with Mr. Young for acting as an executive Director and the overseas business director for a term of three years commencing from the date of his appointment. Mr. Young will hold office until the next annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. Mr. Young will be entitled to a Director's fee and remuneration for performing the duties of the overseas business director totalling RMB1,200,000 per year, which is determined with reference to the Company's performance and profitability, as well as remuneration benchmark in the industry and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Young has confirmed that he does not (i) hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (iii) hold any position in the Company or other members of the Group; and (iv) have any interest in any shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

**Mr. Duan Weiwu (段威武)**, aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng Guangzhou office of Beijing Dacheng Law Offices, LLP (北京大成(廣州)律師事務所) since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm\* (廣東經綸律師事務所) in 2016.

Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (中南政法學院) (now known as Zhongnan University of Economics and Law (中南財經政法大學)) in 1999 with and his master's degree in law from Sun Yat-sen University (中山大學) in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency.

The Company entered into a service agreement with Mr. Duan for acting as an independent non-executive Director for a term of three years commencing from the date of his appointment. Mr. Duan will hold office until the next annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. Mr. Duan will be entitled to a Director's fee of RMB200,000 per year, which is determined with reference to the Company's performance and profitability, as well as remuneration benchmark in the industry and the prevailing market conditions.

As at the date of this announcement, Mr. Duan has confirmed that he does not (i) hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (iii) hold any position in the Company or other members of the Group; and (iv) have any interest in any shares of the Company (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)).

Mr. Duan has also confirmed (a) his independence as regards to each of the factors contained in Rules 3.13(1) to (8) of the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; (b) that he had no past or present financial or other interest in the business of the Group or any connection with any core connected persons (as defined in the Listing Rules) of the Company; and (c) that there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above, there is no other matter in relation to the appointment of Mr. Young as an executive Director and Mr. Duan as an independent non-executive Director that is required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules, nor that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend a warm welcome to Mr. Young and Mr. Duan in joining the Board.

## **CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee.

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Meng**  
*Chairman*

Hong Kong, 8 April 2025

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.*

\* *for identification only*